have become more price-sensitive, and pointed to vVardis’ ongoing losses and reliance on a single customer as sticking points during the roadshow. The broader takeaway isn’t that healthcare can’t IPO: the sector often gets labeled “defensive” because demand for treatment doesn’t swing much with the economy. But deals like this one can reset expectations for how much investors will pay, especially for early-stage healthcare companies without diversified revenue.
Why should I care?
For markets: VVardis’ $18 IPO that still fell 22% raises the bar for other healthcare listings.
When a company prices below its marketed range, underwriters are usually trying to build in a small day-one cushion so trading looks orderly and the deal becomes a friendly reference point for the next issuer. vVardis didn’t get that cushion: opening at $14 and closing down 22% signals that demand “cleared” at a meaningfully lower price once public trading began. That weak first-day print quickly becomes a live comparable in other roadshows, giving investors more leverage to push for lower valuations, smaller deal sizes, or clearer supports, like more transparent customer concentration and a tighter path to profitability, for other loss-making healthcare candidates.
